Anti-TIGIT Therapy: Overview of Current Clinical Evidence and Key Ongoing Trials

Decera Clinical Education Oncology Podcast · Apr 15, 2022 · 22m

In this episode, Jyoti D. Patel, MD, and Ani Balmanoukian, MD, discuss several studies investigating agents targeting TIGIT, an emerging immune checkpoint target with promising results in PD-L1-positive NSCLC. The episode includes a review of phase II data on the use of tiragolumab plus atezolizumab in NSCLC, the use of PD-L1 as a marker of response, the potential role of anti-TIGIT therapies in solid tumors, and ongoing trials in lung cancer including SKYSCRAPER-01, SKYSCRAPER-02, SKYSCRAPER-03, and SKYSCRAPER-05.

Presenters:

Jyoti D. Patel, MD

Professor of Medicine

Division of Hematology…